Skin Cancer News and Research RSS Feed - Skin Cancer News and Research

Skin cancer is the most common type of cancer in the U.S. It occurs in more than a million people each year, including many older people. There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Of the three, melanoma is the most serious. Skin cancer occurs when abnormal cells form and multiply in an uncontrolled way in the epidermis, or abnormal cells from the epidermis invade the dermis of the skin. Basal cell carcinoma, squamous cell carcinoma, and melanoma are skin cancers that are named for the epidermal cells from which they develop.
Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Live imaging study reveals link between wound-associated inflammation and skin cancer risk

Researchers in the United Kingdom and Denmark have studied the "see-through" larvae of zebrafish to reveal how wound healing leads to skin cancer. Live imaging shows neutrophils, the protective inflammatory cells of the body's immune system, diverted from an induced wound to any nearby precancerous skin cells. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Magnolias are prized for their large, colorful, fragrant flowers. Does the attractive, showy tree also harbor a potent cancer fighter? [More]
Targeted molecular-imaging method could help identify early stages of prostate cancer

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies. [More]
British Skin Foundation introduces Molly the Mole wristband to raise awareness of skin cancer

British Skin Foundation introduces Molly the Mole wristband to raise awareness of skin cancer

Nice to meet you! Skin cancer can come at any time so it’s important to remember to check your moles regularly. I don’t mean moles like me, but the ones on your body. [More]
UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas. [More]
Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine. [More]
Mayo Clinic, TGen researchers help launch national clinical trial to treat advanced skin cancer patients

Mayo Clinic, TGen researchers help launch national clinical trial to treat advanced skin cancer patients

Mayo Clinic and the Translational Genomics Research Institute are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer. [More]
Many people seem confused by sunscreen terminology

Many people seem confused by sunscreen terminology

Consumers may need more help navigating the sunscreen aisle. A new Northwestern Medicine study found that many people seem to be confused by sunscreen terminology. [More]
Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya. [More]
UK dermatologist explains the facts on vitamin D and sun exposure

UK dermatologist explains the facts on vitamin D and sun exposure

Sometimes it can be hard to weigh up the benefits of vitamin D versus sun exposure. We talk to Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson who explains. [More]
UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern researchers reveal how the body controls glucose transport

UT Southwestern Medical Center scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels, an important process that when abnormal can promote diabetes, cancer, and rare genetic diseases. [More]
Simon Fraser University's Maryam Sadeghi to unveil MoleScope at World Congress of Dermatology

Simon Fraser University's Maryam Sadeghi to unveil MoleScope at World Congress of Dermatology

Simon Fraser University PhD graduate Maryam Sadeghi will unveil MoleScope, an innovative hand-held tool that uses a smartphone to monitor skin for signs of cancer, at the World Congress of Dermatology conference in Vancouver June 9-13. [More]
Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada. [More]
Investigators patent novel technique for detecting carcinomas in oral mucosa

Investigators patent novel technique for detecting carcinomas in oral mucosa

Malignant tumours of the oral cavity are the sixth leading cause of cancer-related deaths worldwide. As such, a fast and accurate diagnosis is key to maximising the probability of successful treatment and the hope and quality of life of patients. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore. [More]
Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening. [More]
Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors. [More]
Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. [More]
Advertisement